Literature DB >> 23838915

Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.

M Petrillo1, G Ferrandina, A Fagotti, G Vizzielli, P A Margariti, Anchora L Pedone, C Nero, F Fanfani, Giovanni Scambia.   

Abstract

PURPOSE: To compare the timing and pattern of recurrence in patients with advanced ovarian cancer (AOC) receiving primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS).
METHODS: We retrospectively evaluated a consecutive series of 175 stage IIIC-IV epithelial ovarian cancer patients, with diffuse peritoneal carcinomatosis documented at initial surgical exploration. Forty patients received complete PDS, and the remaining 135 were treated with NACT followed by IDS with absent residual tumor after surgery.
RESULTS: No differences were observed in the distribution of clinical pathological characteristics at the time of diagnosis between the two groups. The median follow-up was 31 months (range 9-150 months). We observed 20 (50.0%) recurrences in the PDS group compared to 103 (76.3%) in the IDS group (p = 0.001). Duration of primary platinum-free interval (PFI) was shorter in IDS compared to PDS group (13 vs. 21 months, respectively; p = 0.014). A significantly higher percentage of patients in the IDS group experienced platinum-resistant recurrences (35.9 vs. 5.0%; p = 0.006) and carcinomatosis at the time of relapse (57.3 vs. 20.0%; p = 0.0021). Finally, in women with platinum-sensitive recurrence, we observed a shorter secondary PFI in the IDS compared to PDS group (p = 0.006).
CONCLUSIONS: We documented a better behavior of recurrent disease in AOC patients with diffuse peritoneal carcinomatosis treated with complete PDS compared to women submitted to NACT followed by IDS with no residual tumor after surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838915     DOI: 10.1245/s10434-013-3091-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?

Authors:  Yuki Himoto; Paulina Cybulska; Fuki Shitano; Evis Sala; Junting Zheng; Marinela Capanu; Stephanie Nougaret; Ines Nikolovski; Hebert A Vargas; Wei Wang; Jennifer J Mueller; Dennis S Chi; Yulia Lakhman
Journal:  Gynecol Oncol       Date:  2019-09-12       Impact factor: 5.482

Review 2.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

3.  Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.

Authors:  Yanlin Luo; Maria Lee; Hee Seung Kim; Hyun Hoon Chung; Yong Sang Song
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

4.  Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.

Authors:  Borut Kobal; Marco Noventa; Branko Cvjeticanin; Matija Barbic; Leon Meglic; Marusa Herzog; Giulia Bordi; Amerigo Vitagliano; Carlo Saccardi; Erik Skof
Journal:  Radiol Oncol       Date:  2018-09-11       Impact factor: 2.991

5.  Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer.

Authors:  Shinichi Tate; Kyoko Nishikimi; Kazuyoshi Kato; Ayumu Matsuoka; Michiyo Kambe; Takako Kiyokawa; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2019-12-09       Impact factor: 4.401

Review 6.  Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?

Authors:  Michele Moschetta; Stergios Boussios; Elie Rassy; Eleftherios P Samartzis; Gabriel Funingana; Mario Uccello
Journal:  Ann Transl Med       Date:  2020-12

7.  Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer.

Authors:  Martina Aida Angeles; Bastien Cabarrou; Antonio Gil-Moreno; Asunción Pérez-Benavente; Emanuela Spagnolo; Agnieszka Rychlik; Carlos Martínez-Gómez; Frédéric Guyon; Ignacio Zapardiel; Denis Querleu; Claire Illac; Federico Migliorelli; Sarah Bétrian; Gwénaël Ferron; Alicia Hernández; Alejandra Martinez
Journal:  J Gynecol Oncol       Date:  2021-08-13       Impact factor: 4.401

8.  ROR1 expression correlated with poor clinical outcome in human ovarian cancer.

Authors:  Huilin Zhang; Jinrong Qiu; Chunping Ye; Dazhen Yang; Lingjuan Gao; Yiping Su; Xiaojun Tang; Ning Xu; Dawei Zhang; Lin Xiong; Yuan Mao; Fengshan Li; Jin Zhu
Journal:  Sci Rep       Date:  2014-07-24       Impact factor: 4.379

9.  Feasibility and outcome of primary laparoscopic cytoreductive surgery for advanced epithelial ovarian cancer: a comparison to laparotomic surgery in retrospective cohorts.

Authors:  Huamao Liang; Hongyan Guo; Chunyu Zhang; FuLi Zhu; Yu Wu; Kun Zhang; Hua Li; Jinsong Han
Journal:  Oncotarget       Date:  2017-11-03

Review 10.  Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.

Authors:  Kathryn Mills; Katherine Fuh
Journal:  F1000Res       Date:  2017-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.